Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Insider Trading
Over the last 3 months, CTNM insiders made 0 open-market buys and 4 sales, a net sale of -$166K (SEC Form 4). Over the last 6 months, 65 institutions increased and 28 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
4
Net (3m)
-$165.6K
Insider trades by month Buys Sells
Jan
Feb
Mar
Apr
May
Jun
Context3-month price -10.6%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 1, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,170 | $13.16 |
| May 1, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 3,870 | $13.06 |
| May 1, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 300 | $13.84 |
| Apr 6, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,170 | $13.43 |
| Mar 2, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,170 | $15.01 |
| Mar 2, 2026 | Watkins Timofficer: CMO & Head of Development | Sell | 3,611 | $15.02 |
| Mar 2, 2026 | Watkins Timofficer: CMO & Head of Development | Option | 3,611 | $4.50 |
| Feb 26, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Option | 3,824 | $1.01 |
| Feb 26, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 4,300 | $16.03 |
| Feb 26, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Option | 4,300 | $1.01 |
| Feb 26, 2026 | Stengone Carmine N.director, officer: CEO and President | Sell | 2,700 | $16.02 |
| Feb 26, 2026 | Stengone Carmine N.director, officer: CEO and President | Option | 2,700 | $1.26 |
| Feb 26, 2026 | Stengone Carmine N.director, officer: CEO and President | Sell | 4,400 | $16.02 |
| Feb 26, 2026 | Stengone Carmine N.director, officer: CEO and President | Option | 4,400 | $1.26 |
| Feb 26, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 3,824 | $16.01 |
| Feb 20, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 100 | $16.00 |
| Feb 20, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Option | 100 | $1.01 |
| Feb 13, 2026 | Stengone Carmine N.director, officer: CEO and President | Sell | 400 | $16.00 |
| Feb 13, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 400 | $16.00 |
| Feb 13, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Option | 400 | $1.01 |
| Feb 13, 2026 | Stengone Carmine N.director, officer: CEO and President | Option | 400 | $1.26 |
| Feb 5, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 1,170 | $15.25 |
| Feb 5, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Sell | 3,000 | $14.82 |
| Jan 30, 2026 | Watkins Timofficer: CMO & Head of Development | Sell | 811 | $14.48 |
| Jan 30, 2026 | Healy John Stephenofficer: General Counsel and Corp Sec | Grant | 206,411 | $14.26 |
| Jan 30, 2026 | Slover Peter Tofficer: Chief Financial Officer | Grant | 192,000 | $14.26 |
| Jan 30, 2026 | Stengone Carmine N.director, officer: CEO and President | Grant | 445,000 | $14.26 |
| Jan 30, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Grant | 160,000 | $14.26 |
| Jan 30, 2026 | Lorrain Daniel S.officer: Chief Scientific Officer | Grant | 6,500 | $14.26 |
| Jan 30, 2026 | Watkins Timofficer: CMO & Head of Development | Option | 3,611 | $4.50 |
Source: CTNM SEC Form 4 filings, latest Jun 1, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their CTNM positions over the last 6 months (SEC Form 13F).
Increased
65
New positions
48
Reduced
28
Sold out
22
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | Unchanged | 2.8M | May 15, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Increased | 2.8M | Feb 17, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 2.7M | May 18, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 2.5M | May 29, 2026 |
| JANUS HENDERSON GROUP PLC | New Position | 2.4M | Feb 17, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Increased | 2.2M | Feb 17, 2026 |
| JOHNSON & JOHNSON | Unchanged | 2.0M | Mar 18, 2026 |
| JOHNSON & JOHNSON | Unchanged | 2.0M | May 13, 2026 |
| FRANKLIN RESOURCES INC | Increased | 1.9M | Feb 11, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 1.8M | Feb 17, 2026 |
| FRANKLIN RESOURCES INC | Reduced | 1.8M | May 13, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Reduced | 1.7M | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1.5M | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 1.5M | Feb 17, 2026 |
| BAKER BROS. ADVISORS LP | Increased | 1.4M | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.